236 related articles for article (PubMed ID: 37791219)
1. Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
Virk GS; Vajje J; Virk NK; Mannam R; Rehman W; Ghobriel NG; Mian IU; Usama M
Cureus; 2023 Aug; 15(8):e44413. PubMed ID: 37791219
[TBL] [Abstract][Full Text] [Related]
2. Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.
Jagirdhar GSK; Qasba RK; Pattnaik H; Rama K; Banga A; Reddy ST; Flumignan Bucharles AC; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
World J Gastroenterol; 2023 Jun; 29(21):3362-3378. PubMed ID: 37377589
[TBL] [Abstract][Full Text] [Related]
3. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
4. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups.
Ayada I; van Kleef LA; Alferink LJM; Li P; de Knegt RJ; Pan Q
Liver Int; 2022 Feb; 42(2):277-287. PubMed ID: 34953098
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals.
Quek J; Ng CH; Tang ASP; Chew N; Chan M; Khoo CM; Wei CP; Chin YH; Tay P; Lim G; Tan DJH; Lim WH; Chan KE; Teng M; Tan E; Tamaki N; Huang DQ; Siddiqui MS; Young DY; Noureddin M; Muthiah MD
Endocr Pract; 2022 Jul; 28(7):667-672. PubMed ID: 35364328
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
Kim KS; Hong S; Ahn HY; Park CY
Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation.
Zhou BG; Ju SY; Mei YZ; Jiang X; Wang M; Zheng AJ; Ding YB
Front Endocrinol (Lausanne); 2023; 14():1160532. PubMed ID: 37476492
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
[TBL] [Abstract][Full Text] [Related]
13. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis.
Wen W; Li H; Wang C; Chen C; Tang J; Zhou M; Hong X; Cheng Y; Wu Q; Zhang X; Feng Z; Wang M
Front Endocrinol (Lausanne); 2022; 13():934225. PubMed ID: 36187109
[TBL] [Abstract][Full Text] [Related]
15. Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis.
Yang J; Zhang K; Xi Z; Ma Y; Shao C; Wang W; Tang YD
Sleep Breath; 2023 Oct; 27(5):1985-1996. PubMed ID: 36544011
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.
Hegyi PJ; Váncsa S; Ocskay K; Dembrovszky F; Kiss S; Farkas N; Erőss B; Szakács Z; Hegyi P; Pár G
Front Med (Lausanne); 2021; 8():626425. PubMed ID: 33777974
[No Abstract] [Full Text] [Related]
17. Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.
Jagirdhar GSK; Pattnaik H; Banga A; Qasba RK; Rama K; Reddy ST; Bucharles ACF; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512051
[No Abstract] [Full Text] [Related]
18. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
